BLFS Logo

BioLife Solutions, Inc. (BLFS) 

NASDAQ
Market Cap
$1.21B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
459 of 774
Rank in Industry
32 of 48

Largest Insider Buys in Sector

BLFS Stock Price History Chart

BLFS Stock Performance

About BioLife Solutions, Inc.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line …

Insider Activity of BioLife Solutions, Inc.

Over the last 12 months, insiders at BioLife Solutions, Inc. have bought $0 and sold $4.13M worth of BioLife Solutions, Inc. stock.

On average, over the past 5 years, insiders at BioLife Solutions, Inc. have bought $43.05M and sold $53.12M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 927,165 shares for transaction amount of $10.37M was made by Casdin Partners Master Fund, L.P. (10 percent owner) on 2023‑10‑19.

List of Insider Buy and Sell Transactions, BioLife Solutions, Inc.

2024-11-18SaleEVP & Chief Scientific Officer
17,604
0.0372%
$20.05$352,960+24.51%
2024-11-15SaleEVP & Chief Scientific Officer
25,000
0.0532%
$21.17$529,150+20.79%
2024-11-12SaleEVP & Chief Scientific Officer
123
0.0003%
$26.34$3,240-5.62%
2024-11-12SaleChief Quality and Operations
66
0.0001%
$26.34$1,738-5.62%
2024-11-12SaleChief Financial Officer
147
0.0003%
$26.19$3,850-5.62%
2024-11-12SaleChief Marketing Officer
91
0.0002%
$26.34$2,397-5.62%
2024-10-30SaleEVP & Chief Scientific Officer
547
0.0011%
$23.15$12,663+6.23%
2024-10-30SaleChief Quality and Operations
277
0.0006%
$23.15$6,413+6.23%
2024-10-30SaleChief Financial Officer
894
0.0019%
$23.15$20,696+6.23%
2024-10-30SaleChief Marketing Officer
311
0.0006%
$23.15$7,200+6.23%
2024-10-30SaleChief Human Resources Officer
203
0.0004%
$23.15$4,699+6.23%
2024-10-16SaleEVP & Chief Scientific Officer
10,000
0.0208%
$23.17$231,700+7.02%
2024-10-15SaleEVP & Chief Scientific Officer
10,000
0.0209%
$23.28$232,800+2.86%
2024-09-19SaleEVP & Chief Scientific Officer
10,000
0.0215%
$25.47$254,700-6.20%
2024-09-18SaleEVP & Chief Scientific Officer
10,000
0.0218%
$23.90$239,000+1.77%
2024-09-16SaleEVP & Chief Scientific Officer
343
0.0007%
$25.12$8,616-5.30%
2024-09-16SaleChief Quality and Operations
267
0.0006%
$25.12$6,707-5.30%
2024-09-16SaleChief Financial Officer
611
0.0013%
$25.12$15,348-5.30%
2024-09-16SaleChief Revenue Officer
3,070
0.0066%
$25.12$77,118-5.30%
2024-09-16SaleChief Marketing Officer
367
0.0008%
$25.12$9,219-5.30%

Insider Historical Profitability

5.79%
Mathew Aby J.EVP & Chief Scientific Officer
284442
0.6132%
$26.011115<0.0001%
Casdin Partners Master Fund, L.P.10 percent owner
8557165
18.4473%
$26.01140+28.34%
VILLIGER WALTER10 percent owner
3281778
7.0747%
$26.011445<0.0001%
Rice Michael
347085
0.7482%
$26.012123<0.0001%
GIRSCHWEILER THOMASdirector
47774
0.103%
$26.0127

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Casdin Capital$161.52M18.98.71M0%+$07.98
BlackRock$101.34M11.865.46M+0.72%+$720,741.70<0.01
The Vanguard Group$53.21M6.232.87M+11.54%+$5.5M<0.01
Millennium Management LLC$33.63M3.941.81M-21.6%-$9.27M0.02
William Blair Investment Management$32.03M3.751.73M+0.81%+$255,711.750.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.